AR034216A1 - Metodo de extraccion de virus a partir de cultivos celulares y composiciones que comprenden dicho virus - Google Patents
Metodo de extraccion de virus a partir de cultivos celulares y composiciones que comprenden dicho virusInfo
- Publication number
- AR034216A1 AR034216A1 ARP020100923A ARP020100923A AR034216A1 AR 034216 A1 AR034216 A1 AR 034216A1 AR P020100923 A ARP020100923 A AR P020100923A AR P020100923 A ARP020100923 A AR P020100923A AR 034216 A1 AR034216 A1 AR 034216A1
- Authority
- AR
- Argentina
- Prior art keywords
- virus
- detergent
- reovirus
- compositions
- minutes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/765—Reovirus; Rotavirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12251—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Un método para producir virus a partir de un cultivo de células, que comprende los pasos de: (a) proveer un cultivo de células que ha sido infectado por el virus; (b) extraer el virus de las células por adición de un detergente al cultivo e incubación por un período de tiempo; y (c) recolectar el virus. Se pueden extraer virus infecciosos del cultivo con un detergente a una temperatura conveniente, tal como 25°C ó 37°C, para obtener títulos virales altos. Se pueden usar detergentes no iónicos y iónicos. Particularmente, el detergente se selecciona del grupo formado por Tritón X-100, Tween 20, NP-40 y deoxicolato de sodio. Se prefiere que el detergente sea Tritón X-100, en particular a una concentración final del 1%. El cultivo celular se incuba con el detergente en un período de tiempo suficiente como para provocar la ruptura de las células. El período de incubación es preferentemente de 60 minutos o menos, más preferentemente de 30 minutos o menos y más preferentemente aún de 10 minutos. En una realización preferida el virus es un virus sin envoltura. El virus sin envoltura es preferentemente un reovirus, particularmente un reovirus mamífero. Los reovirus de mamíferos son preferentemente reovirus humanos, más preferentemente el serotipo 3 de reovirus y con mayor preferencia el reovirus de la cepa Dearing. Se describen composiciones que comprenden el virus recolectado, en particular composiciones adecuadas para la administración clínica. Preferiblemente el virus es reovirus. Las composiciones pueden también comprender un excipiente y/o vehículo aceptable para uso farmacéutico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27673401P | 2001-03-16 | 2001-03-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR034216A1 true AR034216A1 (es) | 2004-02-04 |
Family
ID=29420186
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020100923A AR034216A1 (es) | 2001-03-16 | 2002-03-14 | Metodo de extraccion de virus a partir de cultivos celulares y composiciones que comprenden dicho virus |
Country Status (14)
Country | Link |
---|---|
US (2) | US6808916B2 (es) |
EP (2) | EP1370643A1 (es) |
JP (2) | JP4087712B2 (es) |
AR (1) | AR034216A1 (es) |
BR (1) | BR0207527A (es) |
CA (1) | CA2437962C (es) |
DK (1) | DK2253701T3 (es) |
ES (1) | ES2500645T3 (es) |
HK (1) | HK1150859A1 (es) |
IL (2) | IL157304A0 (es) |
MX (1) | MXPA03007535A (es) |
NZ (1) | NZ527525A (es) |
WO (1) | WO2002074940A1 (es) |
ZA (1) | ZA200306228B (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1501921T4 (da) | 2002-04-30 | 2012-10-08 | Oncolytics Biotech Inc | Forbedrede virusrensningsmetoder |
EP1634947A4 (en) * | 2003-06-10 | 2007-10-03 | Shimadzu Corp | EXTRACT FROM A CULTURED MAMMALIAN CELL, PROCESS FOR THEIR PREPARATION AND METHOD FOR CELL-FREE PROTEIN SYNTHESIS USING THE EXTRACT |
US7901921B2 (en) | 2004-10-22 | 2011-03-08 | Oncolytics Biotech Inc. | Viral purification methods |
US10260049B2 (en) | 2005-08-01 | 2019-04-16 | Virocure, Inc. | Attenuated reovirus |
US10668119B2 (en) | 2005-08-01 | 2020-06-02 | Virocure, Inc. | Attenuated reovirus |
EP2952583A1 (en) | 2007-03-12 | 2015-12-09 | Oncolytics Biotech Inc. | Reoviruses having modified sequences |
US10369171B2 (en) | 2007-03-13 | 2019-08-06 | Virocure, Inc. | Attenuated reoviruses for selection of cell populations |
AR066649A1 (es) * | 2007-05-21 | 2009-09-02 | Oncolytics Biotech Inc | Reovirus mutantes y metodos de elaboracion y uso de los mismos |
EP2211880A4 (en) * | 2007-10-22 | 2012-11-14 | Oncolytics Biotech Inc | TREATMENT PROCEDURE FOR PROLIFERATIVE DISEASES |
CN201163385Y (zh) * | 2008-01-15 | 2008-12-10 | 昆山渝榕电子有限公司 | 笔记本电脑及其脚垫 |
JP2011520994A (ja) * | 2008-05-27 | 2011-07-21 | オンコリティクス バイオテク,インコーポレーテッド | 腫瘍崩解性レオウイルス療法中の炎症性サイトカイン産生の排除 |
MX339014B (es) * | 2008-05-27 | 2016-05-09 | Oncolytics Biotech Inc | Modulacion de presion intersticial y suministro y distribucion viral oncolitica. |
WO2012075376A2 (en) | 2010-12-02 | 2012-06-07 | Oncolytics Biotech Inc. | Lyophilized viral formulations |
SG190418A1 (en) | 2010-12-02 | 2013-07-31 | Oncolytics Biotech Inc | Liquid viral formulations |
CA2832367A1 (en) | 2011-04-29 | 2012-11-01 | Oncolytics Biotech Inc. | Methods of purifying viruses using gel permeation chromatography |
KR102186997B1 (ko) * | 2013-03-15 | 2020-12-07 | 안선 바이오파르마, 아이엔씨. | 단백질 정제의 신규한 방법 |
EP3068411B1 (en) | 2013-11-15 | 2020-03-18 | Oncolytics Biotech Inc. | Oncolytic viruses and increased cancer treatment regimens |
US10280199B2 (en) | 2014-02-07 | 2019-05-07 | Phibro Animal Health Corporation | Coronavirus proteins and antigens |
WO2016130569A1 (en) * | 2015-02-09 | 2016-08-18 | Mj Biologics, Inc. | A composition comprising pedv antigens and methods for making and using the composition |
DK3172317T3 (da) * | 2014-07-24 | 2019-07-22 | Janssen Vaccines & Prevention Bv | Fremgangsmåde til oprensning af poliovirus fra cellekulturer |
GB201417042D0 (en) * | 2014-09-29 | 2014-11-12 | Fkd Therapies Oy | Method |
WO2023277173A1 (ja) * | 2021-06-30 | 2023-01-05 | 旭化成メディカル株式会社 | ウイルスの回収方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
JPS6344532A (ja) | 1986-08-11 | 1988-02-25 | Biseibutsu Kagaku Kenkyusho:Kk | 豚のレオウイルス感染症ワクチン |
US5614413A (en) * | 1993-07-01 | 1997-03-25 | The Uab Research Foundation | Encapsidated recombinant poliovirus nucleic acid and methods of making and using same |
HRP950097A2 (en) * | 1994-03-08 | 1997-06-30 | Merck & Co Inc | Hepatitis a virus culture process |
US6146873A (en) * | 1994-11-10 | 2000-11-14 | Baxter Aktiengesellschaft | Production of orthomyxoviruses in monkey kidney cells using protein-free media |
EP0968284B1 (en) * | 1996-11-20 | 2006-12-13 | Introgen Therapeutics, Inc. | An improved method for the production and purification of adenoviral vectors |
US6214333B1 (en) * | 1997-07-08 | 2001-04-10 | Texas Heart Institute | Vasoprotective recombinant adenovirus vector containing a human TFPI gene |
US6110461A (en) | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
TWI289158B (en) | 2000-08-10 | 2007-11-01 | Oncolytics Biotech Inc | Method of producing infectious reovirus |
-
2002
- 2002-03-11 CA CA002437962A patent/CA2437962C/en not_active Expired - Lifetime
- 2002-03-11 EP EP02708064A patent/EP1370643A1/en not_active Withdrawn
- 2002-03-11 IL IL15730402A patent/IL157304A0/xx unknown
- 2002-03-11 WO PCT/CA2002/000331 patent/WO2002074940A1/en active IP Right Grant
- 2002-03-11 EP EP10171853.4A patent/EP2253701B1/en not_active Expired - Lifetime
- 2002-03-11 BR BR0207527-0A patent/BR0207527A/pt not_active IP Right Cessation
- 2002-03-11 ES ES10171853.4T patent/ES2500645T3/es not_active Expired - Lifetime
- 2002-03-11 DK DK10171853.4T patent/DK2253701T3/da active
- 2002-03-11 JP JP2002574332A patent/JP4087712B2/ja not_active Expired - Lifetime
- 2002-03-11 NZ NZ527525A patent/NZ527525A/en unknown
- 2002-03-11 MX MXPA03007535A patent/MXPA03007535A/es active IP Right Grant
- 2002-03-14 US US10/097,183 patent/US6808916B2/en not_active Expired - Lifetime
- 2002-03-14 AR ARP020100923A patent/AR034216A1/es unknown
-
2003
- 2003-08-07 IL IL157304A patent/IL157304A/en active IP Right Grant
- 2003-08-12 ZA ZA200306228A patent/ZA200306228B/en unknown
-
2004
- 2004-06-10 HK HK11104931.1A patent/HK1150859A1/xx not_active IP Right Cessation
- 2004-08-10 US US10/916,378 patent/US7186542B2/en not_active Expired - Lifetime
-
2007
- 2007-08-15 JP JP2007211995A patent/JP2007295937A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP1370643A1 (en) | 2003-12-17 |
ES2500645T3 (es) | 2014-09-30 |
US6808916B2 (en) | 2004-10-26 |
EP2253701B1 (en) | 2014-08-13 |
EP2253701A1 (en) | 2010-11-24 |
US20050095692A1 (en) | 2005-05-05 |
CA2437962A1 (en) | 2002-09-26 |
WO2002074940A1 (en) | 2002-09-26 |
HK1150859A1 (en) | 2012-01-13 |
JP2007295937A (ja) | 2007-11-15 |
JP4087712B2 (ja) | 2008-05-21 |
IL157304A (en) | 2010-04-29 |
ZA200306228B (en) | 2004-08-12 |
NZ527525A (en) | 2005-03-24 |
BR0207527A (pt) | 2004-02-25 |
US7186542B2 (en) | 2007-03-06 |
JP2004520841A (ja) | 2004-07-15 |
CA2437962C (en) | 2005-11-15 |
DK2253701T3 (da) | 2014-10-20 |
US20020168764A1 (en) | 2002-11-14 |
MXPA03007535A (es) | 2003-12-11 |
IL157304A0 (en) | 2004-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR034216A1 (es) | Metodo de extraccion de virus a partir de cultivos celulares y composiciones que comprenden dicho virus | |
Weaver et al. | Population bottlenecks and founder effects: implications for mosquito-borne arboviral emergence | |
Maclachlan et al. | Bluetongue | |
Weger-Lucarelli et al. | Vector competence of American mosquitoes for three strains of Zika virus | |
McLean et al. | A novel insect-specific flavivirus replicates only in Aedes-derived cells and persists at high prevalence in wild Aedes vigilax populations in Sydney, Australia | |
AR039783A1 (es) | Metodos mejorados de purificacion viral | |
Guan et al. | Molecular epidemiology of H5N1 avian influenza | |
Aguilar-Setien et al. | Salivary excretion of rabies virus by healthy vampire bats | |
AR033993A1 (es) | Metodo para producir reovirus infeccioso y de mamifero, y composicion de reovirus | |
EA200200604A1 (ru) | Производство вакцин | |
Diagne et al. | Vector competence of Aedes aegypti and Aedes vittatus (Diptera: Culicidae) from Senegal and Cape Verde archipelago for West African lineages of chikungunya virus | |
ES2895148T3 (es) | Procesos para la producción y purificación de composiciones que contienen ácidos nucleicos | |
ES2421543T3 (es) | Método para la preparación de virus y proteínas del PRRS, y kits de pruebas de diagnóstico para su detección | |
Katz et al. | The significance of failure to isolate infectious viruses in cases of subacute sclerosing panencephalitis | |
Del Amo et al. | Experimental infection of house sparrows (Passer domesticus) with West Nile virus strains of lineages 1 and 2 | |
Planzer et al. | In vivo and in vitro propagation and transmission of Toggenburg orbivirus | |
AR079710A1 (es) | Proceso para el cultivo de celulas adherentes | |
Ng et al. | Topographic changes in SARS coronavirus–infected cells at late stages of infection | |
Sudeep et al. | Preliminary findings on Bagaza virus (Flavivirus: Flaviviridae:) growth kinetics, transmission potential & transovarial transmission in three species of mosquitoes | |
Jadi et al. | Chandipura virus growth kinetics in vertebrate cell lines, insect cell lines & embryonated eggs | |
Koptopoulos et al. | The epizootology of caprine herpesvirus (BHV-6) infections in goat populations in Greece | |
Skern | 100 years poliovirus: from discovery to eradication. A meeting report | |
Jørgensen | Indirect fluorescent antibody techniques for demonstration of trout viruses and corresponding antibody | |
Webb et al. | Argentine and Bolivian hemorrhagic fevers (South American hemorrhagic fevers) | |
Koski | A RHABDOVIRUS ISOLATED FROM BROWN TROUT (SALMO TRUTTA m. LACUSTRIS (L.)) WITH LESIONS IN PARENCHYMATOUSn |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |